TransMedics Group, Inc. (TMDX) Return on Assets (ROA): 11.98%
Is TransMedics Group, Inc.’s return on assets (ROA) high or low?
TransMedics Group, Inc.'s return on assets (ROA) of 11.98% is 256% above its 5-year average of -7.68%, near the high end of its 5-year range (-32.78%–17.81%).
As of Saturday, June 20, 2026. 7.83% above its 12-month average of 11.11%.
TMDX Return on Assets (ROA) Chart
TMDX Average Return on Assets (ROA) Chart
TMDX Current vs Average Return on Assets (ROA) Chart
TMDX Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
11.98%
RETURN ON ASSETS (ROA) AVG TTM
11.11%
RETURN ON ASSETS (ROA) AVG 3Y
1.40%
RETURN ON ASSETS (ROA) AVG 5Y
-7.68%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+7.83%
CURRENT VS 3Y AVG
+754.19%
CURRENT VS 5Y AVG
+255.99%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 11.98% | 11.11% | 1.40% | -7.68% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | -12.01% | -13.41% | -10.26% | -6.23% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -163.04% | -172.19% | -99.08% | -83.15% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 1.72% | -6.26% | -11.14% | 1.46% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | -0.58% | 11.88% | 0.12% | -6.73% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -14.19% | -43.49% | -42.71% | -41.26% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | -2.39% | -0.94% | 2.58% | 3.75% |
| Baxter International Inc. (BAX)vs › | $10.27B | -5.53% | -3.64% | -1.62% | 0.47% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -9.07% | -6.92% | -1.48% | 0.07% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 2.01% | 2.19% | 1.89% | 3.83% |
Asset Efficiency
ROA
12.0%
ROE
34.8%
TransMedics Group, Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for TransMedics Group, Inc. (TMDX)?
- The return on assets (ROA) for TMDX stock is 11.98%.
- Is TransMedics Group, Inc.'s return on assets (ROA) high or low?
- TransMedics Group, Inc.'s return on assets (ROA) of 11.98% is 256% above its 5-year average of -7.68%, near the high end of its 5-year range (-32.78%–17.81%).
- What is the TTM average return on assets (ROA) for TransMedics Group, Inc. (TMDX)?
- The TTM average return on assets (ROA) for TMDX stock is 11.11%.
- What is the 3Y average return on assets (ROA) for TransMedics Group, Inc. (TMDX)?
- The 3Y average return on assets (ROA) for TMDX stock is 1.40%.
- What is the 5Y average return on assets (ROA) for TransMedics Group, Inc. (TMDX)?
- The 5Y average return on assets (ROA) for TMDX stock is -7.68%.
TransMedics Group, Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 17.81% |
| 2024-12-31 | 4.41% |
| 2023-12-31 | -3.54% |
| 2022-12-31 | -13.07% |
| 2021-12-31 | -32.78% |
| 2020-12-31 | -18.91% |
| 2019-12-31 | -31.86% |
| 2018-12-31 | -56.35% |
| 2017-12-31 | -56.28% |
| 2016-12-31 | -41.42% |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein